Furthermore, tumor cells can escape the anti-cancer immunity by activating regulatory T lymphocytes that express cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) competing with CD28 of effector T lymphocytes for binding to CD80/CD86 of antigen presenting cells [113]. Here, CD86 is linked to neoplasm.